Loading
Alzheimer Disease / Amnestic Mild Cognitive Disorder / Biomarker Disclosure Protocol · Interventional Study
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed behavioral intervention trial comparing diagnostic disclosure versus biomarker disclosure in patients with amnestic mild cognitive impairment. No results are posted in this registry record; the study assessed health behavior change, advanced planning, research engagement, and retention as primary outcomes over 6 to 24 months.
Interventional, Randomized, Parallel, Open label, Health Services Research purpose. Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder; age from 50 Years. Intervention: Biomarker and Diagnostic Disclosure. Compared with: Diagnostic Disclosure — Active Comparator. n = 102. 1 site: United States.
This is a completed behavioral intervention trial comparing diagnostic disclosure versus biomarker disclosure in patients with amnestic mild cognitive impairment. No results are posted in this registry record; the study assessed health behavior change, advanced planning, research engagement, and retention as primary outcomes over 6 to 24 months.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study addresses whether disclosure of amyloid and tau biomarker status changes patient health behaviors and research engagement. Results may inform counseling practices for cognitive impairment; however, findings are not yet available and should be awaited from published outcomes.
This is a completed registry record with no posted results; it describes an interventional behavioral study in early stages that requires outcome publication to assess efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This study addresses whether disclosure of amyloid and tau biomarker status changes patient health behaviors and research engagement. Results may inform counseling practices for cognitive impairment; however, findings are not yet available and should be awaited from published outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05584241). This is a study registration, not published results. Lead sponsor: University of Michigan. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 102 participants (ACTUAL). Conditions: Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder. Interventions: BEHAVIORAL: Diagnostic Disclosure Protocol; BEHAVIORAL: Biomarker Disclosure Protocol. Primary outcome measures: Post-disclosure health behavior change as measured by the health behavior subscale score , 6 months; Post-disclosure health behavior change as measured by the health communication subscale score , 6 months; Post-disclosure health behavior change as measured by the advanced planning subscale score , 6 months; Post-disclosure health behavior change as measured by the research engagement subscale score , 6 months; Percent participant retention in University of Michigan Memory and Aging Project (UMMAP) study , Up to 24 months. Brief summary: The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.